Steven E. Fleck
Director of Finance/CFO bij CDG Therapeutics, Inc.
Profiel
Steven E.
Fleck has been Chief Financial Officer of CDG Therapeutics, Inc. since April, 2006.
Prior to CDG Therapeutics, he was Director of Accounting for Northfield Laboratories, Inc. from 1998 to 2005.
Mr. Fleck received a BA degree in Economics from the University of Illinois in 1984 and an MBA from Northern Illinois University in 1987.
Actieve functies van Steven E. Fleck
Bedrijven | Functie | Begin |
---|---|---|
CDG Therapeutics, Inc.
CDG Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology CDG Therapeutics, Inc. develops pharmaceutical products. Its peptides are derived from bacterial & plant sources and are selective for certain cancers while avoiding healthy cells. The company was founded by Ananda M. Chakrabarty and Tapas K. Das Gupta in May 2001 and is located in River Forest, IL. | Director of Finance/CFO | 01-04-2006 |
Eerdere bekende functies van Steven E. Fleck
Bedrijven | Functie | Einde |
---|---|---|
Northfield Laboratories, Inc.
Northfield Laboratories, Inc. BiotechnologyHealth Technology The Company's principal activity is to develop, manufacture, market and distribute a hemoglobin-based blood substitute product. The Company's product, PolyHeme(R) blood substitute, provides an alternative to transfused blood for use in the treatment of acute blood loss. The company uses a proprietary process of separation, filtration, chemical modification purification and formulation to produce PolyHeme. PolyHeme is designed to avoid potential undesirable effects such as vasoconstriction, kidney dysfunction, liver dysfunction and gastrointestinal distress. Clinical trials of PolyHeme have been conducted at multiple locations in the United States. The company has entered into license agreements with Pfizer Inc and Hemocare Ltd an Israeli corporation to develop manufacture and distribute PolyHeme in certain European, Middle Eastern and African countries. The Company is in development stage. | Comptroller/Controller/Auditor | 01-01-2005 |
Opleiding van Steven E. Fleck
Northern Illinois University | Masters Business Admin |
University of Illinois | Undergraduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Bedrijven in privébezit | 2 |
---|---|
Northfield Laboratories, Inc.
Northfield Laboratories, Inc. BiotechnologyHealth Technology The Company's principal activity is to develop, manufacture, market and distribute a hemoglobin-based blood substitute product. The Company's product, PolyHeme(R) blood substitute, provides an alternative to transfused blood for use in the treatment of acute blood loss. The company uses a proprietary process of separation, filtration, chemical modification purification and formulation to produce PolyHeme. PolyHeme is designed to avoid potential undesirable effects such as vasoconstriction, kidney dysfunction, liver dysfunction and gastrointestinal distress. Clinical trials of PolyHeme have been conducted at multiple locations in the United States. The company has entered into license agreements with Pfizer Inc and Hemocare Ltd an Israeli corporation to develop manufacture and distribute PolyHeme in certain European, Middle Eastern and African countries. The Company is in development stage. | Health Technology |
CDG Therapeutics, Inc.
CDG Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology CDG Therapeutics, Inc. develops pharmaceutical products. Its peptides are derived from bacterial & plant sources and are selective for certain cancers while avoiding healthy cells. The company was founded by Ananda M. Chakrabarty and Tapas K. Das Gupta in May 2001 and is located in River Forest, IL. | Health Technology |